Estrella Immunopharma, Inc. Quarterly Deferred Income Tax Expense (Benefit) in USD for Q1 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Estrella Immunopharma, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate for Q1 2023.
  • Estrella Immunopharma, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2023 was -$21.7K.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$21.7K Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.